Format

Send to

Choose Destination
Allergy. 2017 Oct;72(10):1475-1484. doi: 10.1111/all.13177. Epub 2017 Jun 9.

Work productivity in rhinitis using cell phones: The MASK pilot study.

Author information

1
MACVIA-France, Contre les MAladies Chroniques pour un VIeillissement Actif en France European Innovation Partnership on Active and Healthy Ageing Reference Site, Montpellier, France.
2
INSERM U 1168, VIMA: Ageing and Chronic Diseases, Epidemiological and Public Health Approaches, Villejuif, France.
3
Université Versailles St-Quentin-en-Yvelines, UMR-S 1168, Montigny le Bretonneux, France.
4
iQ4U Consultants Ltd, London, UK.
5
Kyomed, Montpellier, France.
6
Medical Communications Consultant, MedScript Ltd, Dundalk, Co. Louth, Ireland.
7
Sorbonne Universités, UPMC Paris 06, UMR-S 1136, IPLESP, Equipe EPAR, Paris, France.
8
Department of Respiratory Diseases, Montpellier University Hospital, Montpellier, France.
9
Department of Chest Medicine, Centre Hospitalier Universitaire UCL Namur, Université Catholique de Louvain, Yvoir, Belgium.
10
Laboratory of Clinical Immunology, Department of Microbiology and Immunology, KU Leuven, Leuven, Belgium.
11
Upper Airways Research Laboratory, ENT Department, Ghent University Hospital, Ghent, Belgium.
12
ISGLoBAL, Centre for Research in Environmental Epidemiology (CREAL), IMIM (Hospital del Mar Research Institute), CIBER Epidemiología y Salud Pública (CIBERESP) & Universitat Pompeu Fabra (UPF), Barcelona, Spain.
13
Global Allergy and Asthma European Network (GA2LEN), Comprehensive Allergy-Centre-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Berlin, Germany.
14
Department of Dermatology and Allergy Centre, Odense University Hospital, Odense, Denmark.
15
Woolcock Institute of Medical Research, University of Sydney and Sydney Local Health District, Glebe, NSW, Australia.
16
Laval's Unit, Clinical Medicine, Quebec City, QC, Canada.
17
Hôpital de La Malbaie, La Malbaie, QC, Canada.
18
Personalized Medicine Clinic Asthma & Allergy, Humanitas University, Humanitas Research Hospital, Rozzano, Milano, Italy.
19
Department of Public Health and Primary Care, Leiden University Medical Center, Leiden, The Netherlands.
20
ProAR - Nucleo de Excelencia em Asma, Federal University of Bahia, Bahia, Brazil.
21
GARD Executive Committee, Bahia, Brazil.
22
Peercode DV, Gerdermalsen, The Netherlands.
23
Laboratoire de Pharmacologie Respiratoire UPRES EA220, Pôle des Maladies Respiratoires, Hôpital Foch, Suresnes, France.
24
Global Allergy and Asthma Platform GAAPP, Vienna, Austria.
25
Department of Otorhinolaryngology, Academic Medical Centre, Amsterdam, The Netherlands.
26
Center for Health Technology and Services Research- CINTESIS, Faculdade de Medicina, Universidade do Porto, Porto, Portugal.
27
Allergy Unit, CUF Porto Instituto & Hospital, Porto, Portugal.
28
Institute of Health Policy and Management iBMG, Erasmus University, Rotterdam, The Netherlands.
29
Skin and Allergy Hospital, Helsinki University Hospital, Helsinki, Finland.
30
Department of Respiratory Diseases, Odense University Hospital, Odense, Denmark.
31
Allergology Department, Centre de l'Asthme et des Allergies. Hôpital d'Enfants Armand-Trousseau (APHP), Paris, France.
32
Sorbonne Universités, UPMC Univ Paris 06, UMR_S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Equipe EPAR, Paris, France.
33
Institute of Social Medicine, Epidemiology and Health Economics, Charité - Universitätsmedizin Berlin, Berlin, Germany.
34
Institute for Clinical Epidemiology and Biometry, University of Wuerzburg, Wuerzburg, Germany.
35
Center for Rhinology and Allergology, Wiesbaden, Germany.
36
Department of Immunology, Rheumatology and Allergy, Medical University of Lodz, Lodz, Poland.
37
HARC, Lodz, Poland.
38
Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland.
39
Clinic of Infectious, Chest Diseases, Dermatology and Allergology, Vilnius University, Vilnius, Lithuania.
40
Clínica de Alergia, Asma y Pediatría, Hospital Médica Sur, México City, Mexico.
41
Clinical & Experimental Respiratory Immunoallergy, ENT Department, Hospital Clínic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.
42
Immunoallergy Department, CUF-Descobertas Hospital, Lisbon, Portugal.
43
Health Information and Decision Sciences Department, Faculty of Medicine, University of Porto, Porto, Portugal.
44
Allergy Unit, CUF-Porto Hospital & Institute, Porto, Portugal.
45
CEDOC, Respiratory Research Group, Nova Medical School, Campo dos Martires da Patria, Lisbon, Portugal.
46
Serviço de Imunoalergologia, Centro Hospitalar de Lisboa Central, EPE, Lisbon, Portugal.
47
Sachs' Children and Youth Hospital, Södersjukhuset, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
48
Allergy and Clinical Immunology Department, Hospital CUF-Descobertas, Lisboa, Portugal.
49
Center for Health Technology and Services Research - CINTESIS and Department of Internal Medicine, Centro Hospitalar Sao Joao, Porto, Portugal.
50
Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital and Central Clinical School, Monash University, Melbourne, Vic., Australia.
51
Department of Immunology, Monash University, Melbourne, Vic., Australia.
52
Center for Pediatrics and Child Health, Institute of Human Development, Royal Manchester Children's Hospital, University of Manchester, Manchester, UK.
53
Allergy Department, 2nd Pediatric Clinic, Athens General Children's Hospital "P&A Kyriakou", University of Athens, Athens, Greece.
54
Allergy and Respiratory Diseases, IRCCS San Martino-IST-University, Genoa, Italy.
55
Observational and Pragmatic Research Institute, Singapore City, Singapore.
56
Optimum Patient Care, Cambridge, UK.
57
Academic Centre of Primary Care, University of Aberdeen, Aberdeen, UK.
58
Allergy and Respiratory Research Group, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, UK.
59
Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland.
60
Centre of Medical Informatics, Usher Institute of Population Health Sciences and Informatics, The University of Edinburgh, Edinburgh, UK.
61
Departments of Pediatrics & Child Health and Immunology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada.
62
Imunoalergologia, Centro Hospitalar Universitário de Coimbra and Faculty of Medicine, University of Coimbra, Coimbra, Portugal.
63
Department of ENT, Medical University of Graz, Graz, Austria.
64
Division of Allergy and Clinical Immunology, University of Salerno, Salerno, Italy.
65
Pneumology and Allergy Department, Ciberres and Clinical & Experimental Respiratory Imunoallergy, IDIBAPS, Universitat Barcelona, Barcelona, Spain.
66
Department of Lung Diseases and Clinical Immunology, University of Turku, Turku, Finland.
67
Terveystalo, Allergy Clinic, Turku, Finland.
68
Vilnius University Clinic of Children's Diseases and Public Health Institute, Vilnius, Lithuania.
69
European Academy of Paediatrics (EAP/UEMS-SP), Brussels, Belgium.
70
Queen's University Belfast, Belfast, UK.

Abstract

Allergic rhinitis often impairs social life and performance. The aim of this cross-sectional study was to use cell phone data to assess the impact on work productivity of uncontrolled rhinitis assessed by visual analogue scale (VAS). A mobile phone app (Allergy Diary, Google Play Store and Apple App Store) collects data from daily visual analogue scales (VAS) for overall allergic symptoms (VAS-global measured), nasal (VAS-nasal), ocular (VAS-ocular) and asthma symptoms (VAS-asthma) as well as work (VAS-work). A combined nasal-ocular score is calculated. The Allergy Diary is available in 21 countries. The app includes the Work Productivity and Activity Impairment Allergic Specific Questionnaire (WPAI:AS) in six EU countries. All consecutive users who completed the VAS-work from 1 June to 31 October 2016 were included in the study. A total of 1136 users filled in 5818 days of VAS-work. Symptoms of allergic rhinitis were controlled (VAS-global <20) in approximately 60% of the days. In users with uncontrolled rhinitis, approximately 90% had some work impairment and over 50% had severe work impairment (VAS-work >50). There was a significant correlation between VAS-global calculated and VAS-work (Rho=0.83, P<0.00001, Spearman's rank test). In 144 users, there was a significant correlation between VAS-work and WPAI:AS (Rho=0.53, P<0.0001). This pilot study provides not only proof-of-concept data on the work impairment collected with the app but also data on the app itself, especially the distribution of responses for the VAS. This supports the interpretation that persons with rhinitis report both the presence and the absence of symptoms.

KEYWORDS:

Allergic Rhinitis and its Impact on Asthma; WPAIA:AS; app; rhinitis; work productivity

PMID:
28387952
DOI:
10.1111/all.13177
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center